Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder
MGHTCT
1 other identifier
interventional
29
0 countries
N/A
Brief Summary
The investigators will conduct a randomized placebo-controlled trial of a computerized intervention targeting cognition in 30 teens with autism spectrum disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2015
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2015
CompletedFirst Submitted
Initial submission to the registry
June 8, 2015
CompletedFirst Posted
Study publicly available on registry
June 16, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 2, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 2, 2017
CompletedMarch 27, 2018
March 1, 2018
2.2 years
June 8, 2015
March 26, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Computerized test
6 weeks
Study Arms (2)
Cognitive Training
EXPERIMENTALTargeted Cognitive Training (TCT)
Control Condition
PLACEBO COMPARATORYouth appropriate online games
Interventions
The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
Engaging games not designed to improve cognition
Eligibility Criteria
You may qualify if:
- Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 ASD or previously diagnosed DSM-IV autistic disorder, Asperger's disorder or pervasive developmental disorder not otherwise specified (NOS) and who continue to manifest symptoms in core domains
- Current ASD symptomatology at time of enrollment
- Evidence of decrements in at least one of three target cognitive domains (mental flexibility/abstraction, working memory, or attention).
You may not qualify if:
- Intellectual Disability
- A known comorbid neurodevelopmental disorder with possible association with autism (i.e., fragile X syndrome, tuberous sclerosis, Angelman syndrome, Prader-Willi syndrome, Williams syndrome, neurofibromatosis, mitochondrial disorder).
- Nonverbal or minimal verbal ability
- No computer/internet connection at home
- No family member with e-mail
- Patients likely to have a change in therapeutic treatments within the next 6 weeks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alysa E Doyle, PhD
Massachusetts General Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Psychiatry
Study Record Dates
First Submitted
June 8, 2015
First Posted
June 16, 2015
Study Start
June 1, 2015
Primary Completion
August 2, 2017
Study Completion
August 2, 2017
Last Updated
March 27, 2018
Record last verified: 2018-03